Additional approval required for PSMA-PET in prostate cancer

Additional approval required for PSMA-PET in prostate cancer

0 Comments

/Sebastian Kaulitzki, stock.adobe.com Berlin From July 1, new rules will apply for the approval of positron emission tomography (PET) for prostate cancer patients. Prostate-specific membrane antigen (PSMA) PET is used in advanced prostate cancer to

Rare diseases: Various medicines for additional benefits...

Rare diseases: Various medicines for additional benefits…

0 Comments

/PhotoSG, stock.adobe.com Berlin – The Federal Joint Committee (G-BA) has assessed the additional benefit of various drugs for rare diseases (orphan drugs) because they exceeded the statutory health insurance turnover limit of 30 million euros